See more : Samhyun Co Ltd (437730.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Sonnet BioTherapeutics Holdings, Inc. (SONN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sonnet BioTherapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Prospect Capital Corporation (PSEC-PA) Income Statement Analysis – Financial Results
- JUSUNG ENGINEERING Co., Ltd. (036930.KQ) Income Statement Analysis – Financial Results
- ThroughTek Co., Ltd. (6565.TWO) Income Statement Analysis – Financial Results
- AVITA Medical, Inc. (AVH.AX) Income Statement Analysis – Financial Results
- Fast Finance Pay Corp. (FFPP) Income Statement Analysis – Financial Results
Sonnet BioTherapeutics Holdings, Inc. (SONN)
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.63K | 147.81K | 349.94K | 483.63K | 0.00 | 40.61M | 30.73M | 41.43M | 41.70M | 42.40M | 0.00 | 17.50M | 6.88M | 1.46M | 136.30K | 684.68K | 234.06K |
| Cost of Revenue | 0.00 | 11.81M | 93.26K | 16.63M | 58.31K | 7.93M | 29.94M | 39.41M | 38.38M | 14.04M | 0.00 | 0.00 | 2.76M | 360.81K | 11.08K | 684.68K | 234.06K |
| Gross Profit | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | 32.68M | 791.11K | 2.03M | 3.33M | 28.36M | 0.00 | 17.50M | 4.12M | 1.10M | 125.22K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -7,893.43% | 73.35% | -3,339.55% | 0.00% | 80.47% | 2.57% | 4.89% | 7.98% | 66.89% | 0.00% | 100.00% | 59.87% | 75.35% | 91.87% | 0.00% | 0.00% |
| Research & Development | 5.74M | 11.81M | 21.44M | 16.63M | 9.88M | 2.20M | 154.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 363.88K | 4.55M | 5.80M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.50M | 0.00 | 145.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 3.86M | 4.55M | 5.95M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 935.11K | 2.24M | 2.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 125.50K | 0.00 | 11.05M | 11.05M | 5.19M | 3.45M | 3.36M | 0.00 | -23.29M | 0.00 | 0.00 | 0.00 | -1.12M | -1.14M |
| Operating Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 3.86M | 4.55M | 5.95M | 10.78M | 0.00 | -23.29M | 2.62M | 1.25M | 935.11K | 1.12M | 1.14M |
| Cost & Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 33.80M | 43.95M | 44.32M | 24.82M | 0.00 | -23.29M | 9.75M | 2.18M | 946.19K | 1.13M | 1.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 15.00 | 20.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.54K | 46.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 20.68K | 162.87K | 381.68K | -2.59M | -2.35M | -3.47M | 0.00 | 0.00 | -474.93K | -180.83K | 140.02K | 33.91K | 20.49K |
| Depreciation & Amortization | 0.00 | 75.75K | 93.26K | 95.16K | 58.31K | 3.54M | 1.82M | 2.28M | 2.34M | 2.36M | 0.00 | 0.00 | 383.45K | 87.62K | 11.08K | 11.48K | 11.20K |
| EBITDA | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | -13.15M | -3.71M | -2.93M | 541.15K | -2.73M | 0.00 | -3.91M | -3.24M | -1.18M | -878.82K | -376.05K | -2.21M |
| EBITDA Ratio | -63,617.91% | -12,663.22% | -8,463.34% | -5,163.13% | 0.00% | -11.59% | -4.08% | -0.57% | -0.67% | -31.68% | 0.00% | -33.13% | -47.06% | -80.75% | -644.76% | -54.92% | -942.91% |
| Operating Income | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | -4.71M | -3.07M | -2.52M | -2.62M | -11.49M | 0.00 | -5.80M | -2.87M | -714.31K | -809.89K | -444.49K | -949.99K |
| Operating Income Ratio | -63,617.91% | -12,714.47% | -8,478.34% | -5,187.36% | 0.00% | -11.59% | -9.99% | -6.08% | -6.28% | -27.10% | 0.00% | -33.13% | -41.69% | -48.80% | -594.19% | -64.92% | -405.88% |
| Total Other Income/Expenses | 4.41M | -40.08K | -52.48K | 103.48K | -27.34K | -162.87K | -7.38M | -5.29M | -1.53M | 3.59M | 0.00 | 508.78K | -505.46K | -379.90K | -220.03K | -369.21K | -1.29M |
| Income Before Tax | -7.44M | -18.83M | -29.72M | -24.98M | -24.27M | -4.87M | -8.07M | -7.81M | -4.15M | -14.32M | 0.00 | -5.96M | -3.38M | -1.09M | -1.03M | -813.70K | -2.24M |
| Income Before Tax Ratio | -39,929.30% | -12,741.58% | -8,493.34% | -5,165.97% | 0.00% | -11.99% | -26.26% | -18.85% | -9.95% | -33.78% | 0.00% | -34.07% | -49.04% | -74.75% | -755.62% | -118.84% | -956.45% |
| Income Tax Expense | 0.00 | 0.00 | 52.48K | 22.03K | 6.80M | 162.87K | -701.22K | -644.43K | 198.46K | -187.57K | 0.00 | 0.00 | 19.21K | 14.61K | 0.00 | 0.00 | 0.00 |
| Net Income | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M | -5.03M | -6.85M | -6.79M | -9.08M | -12.14M | 0.00 | -5.96M | -3.17M | -1.10M | -1.01M | -813.70K | -2.24M |
| Net Income Ratio | -39,929.30% | -12,741.58% | -8,508.34% | -5,170.52% | 0.00% | -12.40% | -22.30% | -16.40% | -21.77% | -28.63% | 0.00% | -34.07% | -46.01% | -75.38% | -742.16% | -118.84% | -956.45% |
| EPS | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| EPS Diluted | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| Weighted Avg Shares Out | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| Weighted Avg Shares Out (Dil) | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
Best Penny Stocks to Buy Under $1? 4 To Watch Now
Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1.
4 Penny Stocks To Watch Under $5 With Big News This Week
Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity.
3 Hot Penny Stocks To Watch Under $1, Time To Buy?
Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010...
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored SB101 multiple-dose clinical trial (NCT05352750) of SON-1010...
5 Hot Penny Stocks To Watch This Week With Big News
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy? 5 To Watch For November 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy?
Using Reddit to Find Penny Stocks to Buy? Use These Tips
Here's how to find penny stocks on Reddit right now The post Using Reddit to Find Penny Stocks to Buy? Use These Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company's Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
PRINCETON, NJ / ACCESSWIRE / November 1, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study...
How to Take Advantage of Market Volatility With Penny Stocks
Are these money making tips part of your penny stocks trading strategy? The post How to Take Advantage of Market Volatility With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports